Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prestige Consumer HealthcarePBH -2.24%69 Debt-to-EBITDA is 8.44 as of Jun. 2026, which is 63% above its 10-year median of 5.18. GuruFocus rates PBH with a GF Score™ of 69/100 and a GF Value™ of $70.51 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 681 Drug Manufacturers companies, Prestige Consumer Healthcare ranks worse than 86.2% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Prestige Consumer Healthcare's Debt-to-EBITDA or its related term are showing as below:
PBH'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.89 Med: 5.18 Max: 173.62
Current: 6.61
During the past 13 years, the highest Debt-to-EBITDA Ratio of Prestige Consumer Healthcare was 173.62. The lowest was 2.89. And the median was 5.18.
PBH's Debt-to-EBITDA is ranked worse than 86.2% of 681
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs PBH: 6.61
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Prestige Consumer Healthcare Debt-to-EBITDA Related Terms
Prestige Consumer Healthcare Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PBH vs BCRX, AMLX, SUPN: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Prestige Consumer Healthcare's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prestige Consumer Healthcare Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Prestige Consumer Healthcare's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Prestige Consumer Healthcare's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Prestige Consumer Healthcare (PBH) has a Debt-to-EBITDA of 8.44 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Prestige Consumer Healthcare. This is 63% above median its historical median of 5.18. Over the past decade, Prestige Consumer Healthcare's Debt-to-EBITDA has ranged from 2.89 to 173.62. According to the industry distribution chart, Prestige Consumer Healthcare ranks #587 out of 681 companies in the Drug Manufacturers industry, placing it in the top 86.2%.
Is Prestige Consumer Healthcare's Debt-to-EBITDA too high?
Prestige Consumer Healthcare's current Debt-to-EBITDA of 8.44 is 63% above median its 10-year median of 5.18. Over the past 10 years, this metric has ranged from a low of 2.89 to a high of 173.62. The Drug Manufacturers industry median Debt-to-EBITDA is 1.64. Prestige Consumer Healthcare's value of 8.44 is 414.6% above this industry median. Based on the distribution chart, Prestige Consumer Healthcare ranks #587 out of 681 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Prestige Consumer Healthcare has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Prestige Consumer Healthcare's Debt-to-EBITDA compare to BCRX and AMLX?
According to the Drug Manufacturers industry distribution chart, Prestige Consumer Healthcare ranks #587 out of 681 companies for Debt-to-EBITDA. This places Prestige Consumer Healthcare in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. Prestige Consumer Healthcare's value of 8.44 is 414.6% above this benchmark. Historically, Prestige Consumer Healthcare's own Debt-to-EBITDA has ranged from 2.89 to 173.62 over the past decade. While the company's 10-year median is 5.18 vs. the industry median of 1.64, Prestige Consumer Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prestige Consumer Healthcare's current Debt-to-EBITDA of 8.44 is 414.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Prestige Consumer Healthcare. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prestige Consumer Healthcare's current Debt-to-EBITDA is 8.44, which is 63% above median its own 10-year median of 5.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prestige Consumer Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Prestige Consumer Healthcare (PBH) is currently considered Modestly Undervalued. The stock's GF Value™ is $70.51, compared to a current price of $50.52 — trading 28.4% below its estimated fair value. The current Debt-to-EBITDA is 8.44, which is 63% above median its 10-year median of 5.18 and 414.6% above the Drug Manufacturers industry median of 1.64. Prestige Consumer Healthcare's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Prestige Consumer Healthcare (PBH), the current Debt-to-EBITDA is 8.44 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prestige Consumer Healthcare (PBH) Overvalued in 2026?
Based on GuruFocus' analysis, Prestige Consumer Healthcare stock appears to be undervalued.
The current stock price of $50.52 is trading 28.4% below its estimated GF Value™ of $70.51.
GuruFocus considers Prestige Consumer Healthcare to be Modestly Undervalued.
Key valuation signals for PBH:
Debt-to-EBITDA: 8.44 (63% above median its 10-year median of 5.18)
GF Value™: $70.51 vs. price of $50.52 (28.4% below fair value)
Industry Position: 414.6% above the Drug Manufacturers median (#587 of 681)
No single metric tells the full story. See the PBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
69GF Score
Get the complete analysis for PBH
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBH has been successfully added to your 
